{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:02:40Z","timestamp":1770436960094,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s40261-013-0065-1","type":"journal-article","created":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T21:23:39Z","timestamp":1362086619000},"page":"283-289","source":"Crossref","is-referenced-by-count":8,"title":["Tazarotene Foam versus Tazarotene Gel: A Randomized Relative Bioavailability Study in Acne Vulgaris"],"prefix":"10.1007","volume":"33","author":[{"given":"Michael","family":"Jarratt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cary P.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra B.","family":"Ali\u00f3 Saenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,1]]},"reference":[{"issue":"3","key":"65_CR1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3810\/pgm.2011.05.2294","volume":"123","author":"P Hsu","year":"2011","unstructured":"Hsu P, Litman GI, Brodell RT. Overview of the treatment of acne vulgaris with topical retinoids. Postgrad Med. 2011;123(3):153\u201361.","journal-title":"Postgrad Med"},{"issue":"14","key":"65_CR2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJM198510033131401","volume":"313","author":"EJ Lammer","year":"1985","unstructured":"Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837\u201341.","journal-title":"N Engl J Med"},{"key":"65_CR3","unstructured":"Tazorac\u00ae (tazarotene cream, 0.1%): US prescribing information. Irvine: Allergan, Inc.; 2001."},{"key":"65_CR4","unstructured":"Tazorac\u00ae (tazarotene gel, 0.1%): US prescribing information. Irvine: Allergan, Inc.; 2011."},{"issue":"3","key":"65_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1517\/17425250902721250","volume":"5","author":"R Talpur","year":"2009","unstructured":"Talpur R, Cox K, Duvic M. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol. 2009;5(3):195\u2013210.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"65_CR6","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1067\/mjd.2000.108321","volume":"43","author":"A Menter","year":"2000","unstructured":"Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol. 2000;43:S31\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"65_CR7","unstructured":"Fabior\u00ae (tazarotene foam, 0.1%): US prescribing information. Research Triangle Park: Stiefel Laboratories, Inc.; 2012."},{"key":"65_CR8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1211\/jpp.62.01.0011","volume":"62","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, Jones SA, Brown MB. Dynamic foams in topical drug delivery. J Pharm Pharmacol. 2010;62:678\u201384.","journal-title":"J Pharm Pharmacol"},{"key":"65_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.04.028","volume":"394","author":"A Arzhavitina","year":"2010","unstructured":"Arzhavitina A, Steckel H. Foams for pharmaceutical and cosmetic application. Int J Pharm. 2010;394:1\u201317.","journal-title":"Int J Pharm"},{"key":"65_CR10","unstructured":"Data on file, Stiefel, a GSK company, 2012."},{"issue":"10","key":"65_CR11","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2165\/00003088-200342100-00004","volume":"42","author":"Z Yu","year":"2003","unstructured":"Yu Z, Sefton J, Lew-Kaya D, et al. Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin. Clin Pharmacokinet. 2003;42(10):921\u20139.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0065-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0065-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0065-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:50Z","timestamp":1559489330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0065-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,1]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["65"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0065-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,1]]}}}